Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash from Investing Activities (2020 - 2025)

Tango Therapeutics has reported Cash from Investing Activities over the past 6 years, most recently at -$135.7 million for Q4 2025.

  • Quarterly results put Cash from Investing Activities at -$135.7 million for Q4 2025, down 360.69% from a year ago — trailing twelve months through Dec 2025 was -$40.9 million (down 147.45% YoY), and the annual figure for FY2025 was -$40.9 million, down 147.45%.
  • Cash from Investing Activities for Q4 2025 was -$135.7 million at Tango Therapeutics, down from $47.5 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for TNGX hit a ceiling of $52.1 million in Q4 2024 and a floor of -$152.2 million in Q3 2021.
  • Median Cash from Investing Activities over the past 5 years was $16.0 million (2022), compared with a mean of -$3.5 million.
  • Biggest five-year swings in Cash from Investing Activities: skyrocketed 635.74% in 2022 and later plummeted 472.1% in 2023.
  • Tango Therapeutics' Cash from Investing Activities stood at -$45.2 million in 2021, then surged by 72.12% to -$12.6 million in 2022, then skyrocketed by 368.56% to $33.9 million in 2023, then soared by 53.79% to $52.1 million in 2024, then tumbled by 360.69% to -$135.7 million in 2025.
  • The last three reported values for Cash from Investing Activities were -$135.7 million (Q4 2025), $47.5 million (Q3 2025), and $16.8 million (Q2 2025) per Business Quant data.